PDCD1 and hepatocellular carcinoma: While anlotinib and anti‐PD‐1 independently yielded significant tumour growth reduction in HCC models, the combined regimen demonstrated more potent inhibition of tumour growth, as evidenced by measurements of tumour volume and weight (Figure 1E and Figure S2A, B).